TrialHuman vaccines & immunotherapeutics2024

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).

Alvino Maestri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.